Wills Eye Hospital has announced that it has treated the first RESCUE trial patient in the United States enrolled in an FDA-approved gene therapy vision research study. A product called GS010 (GenSight Biologics), can be injected right into the eye and, in a sense, “re-wire” or lower the patient’s risk for getting the disease. The patient has [Read More]
Category: Latest News
Similarity of Anti-VEGF Drugs Confirmed For DME Treatment
A rigorous clinical trial has found that individuals with diabetic macular edema (DME), whose visual acuity is 20/50 or worse, gained more improvement with Eylea than with Avastin. Aside from that, no significant difference was found among the three anti-VEGF drugs (including Lucentis) in subjects with 20/32 or 20/40 vision at the start of treatment. By two years, 41 percent of participants in the [Read More]
Large Study Shows 1 in 5 People With Vision Loss Experience Hallucinations
A new study conducted by the Canadian National Institute for the Blind (CNIB) has found that one in five Canadians with vision loss who were surveyed experience visual hallucinations, known as Charles Bonnet Syndrome (CBS). The study, titled “Prevalence of visual hallucinations in a national low vision client population”, published in the most recent issue [Read More]
Future Sustained Drug Delivery Methods for Choroidal Neovascularization
During the American Academy of Ophthalmology’s Retina Subspecialty Day in 2015, Peter K. Kaiser, MD, described six alternative methods being looked at for delivery of anti-VEGF drugs into the retinas of individuals experiencing choroidal neovascularization (CNV). Periodic intraocular injections are currently the only procedure for halting damaging blood vessel growth and leakage. Injections are expensive, time-consuming, and burdensome on the patients, so [Read More]
New Combination Therapy Treats Retinal Damage in Diabetics
Aerpio Therapeutics, Inc. has announced promising results from their “TIME-2” study of AKB-9778 as a treatment for diabetic retinopathy (DR). AKB-9778 alone and in combination with Lucentis® (ranibizumab) improved underlying retinopathy by 10.0%, and 11.4% compared to 8.8% of patients receiving Lucentis® alone. The clinical findings were presented by Pravin U. Dugel, M.D., at the [Read More]